Elevation of CD8+CD11b+Leu-8- T cells is associated with the humoral immunodeficiency in myeloma patients

Clinical and Experimental Immunology

Volumn 109, Issue 2, 1997, Pages 310-316

  Walchner, M ^a   Wick, M ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Immunoglobulin regulation; Monoclonal; Myeloma; Polyclonal T cells

Indexed keywords

CD11B ANTIGEN; CD8 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; POKEWEED MITOGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; MALE; MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0030807609     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4451342.x     Document Type: Article

References (44)

1. Wierenga EA, Snoek M, Jansen HM, Bos JD, van Lier RAW, Kapsenberg M. Human atopen-specific types 1 and 2 helper cell clones. J Immunol 1991; 147:2942-9.
2. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995; 16:374-9.
3. + T cells into subpopulations with cytokine profiles. J Immunol 1995; 155:2928-37.
4. + T lymphocytes into IL-4- and IL-5-producing cells. J Immunol 1994; 153:4862-71.
5. + TCl cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. J Exp Med 1995; 182:1505-15.
6. + T lymphocytes provide helper activity for IgE synthesis in human immunodeficiency virus-infected patients with hyper-IgE. J Exp Med 1995; 181:423-8.
7. + cells to support autoantibody synthesis. Arthritis Rheum 1993; 33:1216-25.
8. Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994; 15:288-94.
9. Walchner M, Leib-Mösch C, Germaier H, Plewig G, Kind P. Endogenous retroviral sequences in the pathogenesis of systemic autoimmune disease. Arch Dermatol, in press.
10. + subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J Immunol 1992; 148:182-8.
11. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996; 39:1050-4.
12. Llorente L, Zhou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181:839-44.
13. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176:1319-26.
14. Merico F, Bergui L, Gregoretti MG et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993; 92:27-31.
15. Klein B. Cytokine, cytokine receptors, transduction signals and oncogenes in human multiple myeloma. Sem Hematol 1995; 32:4-19.
16. + cells enhance IgG production by antibody-secreting B cells. Clin Immunol Immunopathol 1991; 58:352-65.
17. + T cells in peripheral blood of multiple myeloma patients. J Clin Immunol 1988; 8:259-65.
18. + T cells. J Immunol 1993; 151:2237-46.
19. + cytotoxic T cell actuation and memory in virus infection. J Immunol 1992; 149:1326-33.
20. Dianzani U, Pileri A, Boccadoro M et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988; 72:1064-8.
21. Massaia M, Attisano T, Peola S et al. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 1993; 82:1787-97.
22. + T cells in patients with multiple myeloma and paraproteinemia. Blood 1996; 87:3297-306.
23. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995; 86:3043-9.
24. Alexanian R, Dimopoulos MA. Management of multiple myeloma. Sem Hematol 1995; 32:20-30.
25. Portier M, Zhang YG, Caron E, Lu ZY, Bataille R, Klein B. Gamma-interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependant myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81:3076-82.
26. Sawamura M, Murakami H, Tamura J et al. Tumour necrosis factor-alpha and interleukin 4 promote the differentiation of myeloma cell precursors in multiple myeloma. Brit J Haematol 1994; 88:17-23.
27. O'Gorman MRG, Oger JJF. Regulation of in vitro PWM-induced IgG secretion in humans. Cell Immunol 1989; 118:435-47.
28. Ratcliffe MJ, Julius MH. T-dependent activation of resting B cells mediated by concanavalin A. Eur J Immunol 1984; 14:280-3.
29. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma - new biological insights and advances in therapy. Blood 1989; 73:865-79.
30. Potter M. Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol Oncol Clin North Am 1992; 6:211-23.
31. Billadeau D, Ahmann G, Greipp P, van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178:1023-31.
32. Jensen GS, Belch AJ, Kherani F, Mant MJ, Ruether BA, Pilarski LM. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD11b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Stand J Immunol 1992; 36:843-53.
33. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995; 85:436-47.
34. Van Camp B, Durie BGM, De Waele M et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76:377-82.
35. Durie B, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 26:842-54.
36. + T lymphocytes that express neither CD4 nor CD8 antigens. J Exp Med 1986; 164:339-44.
37. Sedgwick JD, Holt PD. A solid phase immunoenzymatic technique for the enumeration of specific antibody secreting cells. J Immunol Methods 1983; 57:301-9.
38. Pilarski LM, Andrews EJ, Serra HM, Ruether BA, Mant MJ. Comparative analysis of immunodeficiency in patients with monoclonal gammopathy of undetermined significance and patients with untreated multiple myeloma. Scand J Immunol 1989; 29:217-28.
39. + cells. Brit J Haematol 1995; 90:625-32.
40. Sonneveld P, Schoester M, de Leeuw K. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. Brit J Haematol 1991; 79:589-94.
41. Peest D, Leo R, Deicher H. Tumor-directed cytotoxicity in multiple myeloma-the basis for an experimental treatment approach with interleukin 2. Stem Cells Dayt 1995: 13:72-76s.
42. Yi Q, Holm G, Lefvert AK. Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin Exp Immunol 1996; 104:359-65.
43. + regulatory T cells via IFN-γ. Scand J Immunol 1996; 43:421-30.
44. Hilbert DM, Shen MY, Rapp UR, Rudikoff S. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc Natl Acad Sci USA 1995; 92:649-53.